Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus shareholders Filed three international patent enforcement lawsuits against Pfizer and BioNTech related to lipid […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
